Etoposide

For research use only. Not for use in humans.

目录号:S1225 别名: VP-16, VP-16213

Etoposide Chemical Structure

CAS No. 33419-42-0

Etoposide (VP-16, VP-16213) 是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。Etoposide可诱导自噬、线粒体自噬和细胞凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 749.41 现货
RMB 575.72 现货
RMB 2290.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Etoposide发表文献145篇:

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

产品描述 Etoposide (VP-16, VP-16213) 是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。Etoposide可诱导自噬、线粒体自噬和细胞凋亡。
靶点
Topo II [2]
(Cell-free assay)
体外研究

Etoposide通过与Topoisomerase II 和 DNA形成复合物而抑制DNA合成,诱导双链DNA断裂,且阻碍通过 Topoisomerase II结合修复。DNA持续断裂阻碍进入细胞有丝分裂期,进而导致细胞死亡。Etoposide主要作用于细胞周期的G2期和S期。[1] Etoposide 抑制鼠类血管肉瘤细胞系 (ISOS-1) 生长,IC50 为0.25 μg/mL。Etoposide 抑制人类白血病成淋巴细胞系CCRF-CEM的四倍体克隆,IC50为0.6 μM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD5eo11UUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> NF7rVZczPTl4MEK4Ni=>
KellyCis83 NY[yUWxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX2R3I6UUN3ME2wMlE36oDLwsJihKkxNjB{IN88US=> NUTHZZBqOjV7NkCyPFI>
SK-N-AS NI\PbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqyOYgzUUN3ME2wMlI16oDLwsJihKkxNjB|IN88US=> MUWyOVk3ODJ6Mh?=
SK-N-ASCis24 M2jrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP MYiyOVk3ODJ6Mh?=
U87 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vh[|AuPTBizszN Ml7uOFghcA>? NXryUGFS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDzbYxq[mmwaX6= MnfTNlU4PTB{N{O=
HCT116 NHzKb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvINE42NTJwNTFOwG0> NGm1NGg1QMLiaNMg NXrOUHpvUUN3ME2xMlc{yqEEsdMgNE4zOcLizszN MYKyOVc1Pjd4Mx?=
HT-29 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWju[ZN5OC53LUKuOUDPxE1? MXG0POKhcMLi MlT3TWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? NHLCSGEzPTd2Nke2Ny=>
Caco2 NHzJPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPTNE42NTJwNTFOwG0> MojXOFjDqGkEoB?= M1PiTmlEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= NVq5R3gxOjV5NE[3OlM>
COLO 205 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\ySGxlOC53LUKuOUDPxE1? NYDOO4JIPDkEoHlCpC=> MULJR|UxRTFwNkJCpOKyyqByLkCyxsDPxE1? NVS5[4M{OjV5NE[3OlM>
SW480 NInn[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqwMlUuOi53IN88US=> NX2x[HZvPDkEoHlCpC=> MnPlTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP M4\IXlI2PzR4N{[z
HEK293T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\XWGsyNTVizszN MlHhOFjDqGkEoB?= MmnzTWM2OD1{LkSyxsDDucLiMD6wOeKh|ryP MkXDNlU4PDZ5NkO=
Hep3B  NVuwZWlKTnWwY4Tpc44hSXO|YYm= Mki4NVAh|ryP NFvMfGU1QMLiaNMg NFq3VYNz\WS3Y3XzJJRp\SCnbnjhcoNqdmdiZX\m[YN1KG:oIFLNVE03 MViyOVY{OzV4NB?=
Hep3B  MlfySpVv[3Srb36gRZN{[Xl? MkXmNE4yNTFyIN88US=> NEDrZmczPCCq MXLzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? Mlr1NlU3OzN3NkS=
HEK293 M{HUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrCeFFiUUN3ME23MlE1yqEEsdMgNE4{PsLizszN M1HiNVI2PjB|MUKy
DU145 NXnYWphpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO2TWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP NUm5S|VMOjV4MEOxNlI>
HCT15 NX\DZo5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPoTWM2OD1yLkixxsDDucLiMD6wNeKh|ryP NV\jdGY2OjV4MEOxNlI>
T47D MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwMUlCpOKyyqByLkGxxsDPxE1? MmfENlU3ODNzMkK=
SMMC-7721 MVTGeY5kfGmxbjDBd5NigQ>? NYH5cWFRPDBizszN MUm0PEBp MXjEUXNQ NE\WZWJqdmS3Y3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdg>? MVuyOVU1PDN4MR?=
MDA-MB-231 M4XIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;sdWtRPzMEoHi= MoS2TWM2OD1{MT6yxsDDucLiND6yxsDPxE1? NEXw[I4zPTR6NkKxPS=>
MCF-7 M1SyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\0bVY4OsLiaB?= MU\JR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? MnjWNlU1QDZ{MUm=
Jurkat MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDmRVY4OsLiaB?= M1HWfGlEPTB;MT6yxsDDucLiMT61xsDPxE1? NGnTSmkzPTR6NkKxPS=>
HeLa M{X1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH6O|LDqGh? MV;JR|UxRTNwOdMgxtHDqDJwM9Mg{txO M2rtNFI2PDh4MkG5
MCF7  NXHFWYU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW2NVE4PS1zMECg{txO NIjMfWs4KGR? MkT6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFe0PZEzPTR5Mk[xPS=>
K562 NYLDNmNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NuKhcA>? MWHJR|UxRTBwMkpCpO69VQ>? NEPaZYYzPTJ6Mk[1Ny=>
K/VP.5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:3NuKhcA>? MXvJR|UxRTRwOdMg{txO NEezfmszPTJ6Mk[1Ny=>
SH-EP  MX;GeY5kfGmxbjDBd5NigQ>? NWPI[I5rOjEEoN88[{9udA>? NU\yd4I4OjUEoHi= MmG1bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= MlLXNlUzPjF7OEG=
SCC25 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LYRlI1yqCq NHLnfZNKSzVyPUSzMlPDqMLzwrCxMlEzyqEQvF2= M1P0cFI2OjJyN{K5
CAL27 NYPMdGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr5S3UzPMLiaB?= NEK0eXZKSzVyPUWyMlHDqMLzwrCxMlA6yqEQvF2= NVWwdZFwOjV{MkC3Nlk>
FaDu NVfMW45uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPESFYzPMLiaB?= NXTw[JVKUUN3ME2yOU45QcLiwsJCpFEvOTQEoN88US=> MkXuNlUzOjB5Mkm=
SCC25 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXIVpY1QMLiaB?= NV7tTnJ1UUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> NVHrSZFDOjV{MkC3Nlk>
CAL27 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jnWVQ5yqCq MYLJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP MX:yOVIzODd{OR?=
FaDu NIjWdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILob401QMLiaB?= Mn:0TWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP NFr0Rm8zPTJ{MEeyPS=>
SCC25 NWTTW49DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrYO3E4OsLiaB?= MnXOTWM2OD16LkSxxsDDucLiMT6xNeKh|ryP NIK4T|AzPTJ{MEeyPS=>
CAL27 NEmzd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GyN|czyqCq NFPq[m5KSzVyPUSuNlfDqMLzwrCxMlE1yqEQvF2= MYWyOVIzODd{OR?=
FaDu NV3r[HVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3DO|LDqGh? NWrJPGdXUUN3ME21MlAzyqEEsdMgNU4yPcLizszN M{PXTFI2OjJyN{K5
MCF-7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrrbFc1QMLiaNMg M1GwUWROW09? MnTITWM2OD15LkNCpOKyyqByLklCpO69VQ>? M37Q[|I2OjF4M{e4
T-47D M3\JeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7Dd2NlPDkEoHlCpC=> MonPSG1UVw>? NIXnT49KSzVyPUeuO:KhyrIEoECuO:Kh|ryP M1rvVlI2OjF4M{e4
MDA-MB-231 M{LKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPuTJh3PDkEoHlCpC=> M1vIdWROW09? MV;JR|UxRTF{LklCpOKyyqBzLkFCpO69VQ>? MmO4NlUzOTZ|N{i=
DU145 M3znVWFxd3C2b4Ppd{BCe3OjeR?= M1fBZ|ExNTFyMDFOwG0> MVe4JIg> NIDpTYtFVVOR MX3pcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NUG5VYJbOjVzNEm2PFE>
DU145 stem-like M3;aUGFxd3C2b4Ppd{BCe3OjeR?= M2n1PVExNTFyMDFOwG0> NIXpNnc5KGh? MmS3SG1UVw>? MkPUbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mo\ONlUyPDl4OEG=
DU145 NGToWIhHfW6ldHnvckBCe3OjeR?= NU\5cYFSOTBvMUCwJO69VQ>? M4fwZ|IhcA>? NGrlPJBFVVOR NXTrd3NScW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlrGNlUyPDl4OEG=
DU145 stem-like NULScnJwTnWwY4Tpc44hSXO|YYm= MWGxNE0yODBizszN MnPYNkBp NILG[YhFVVOR MX7pcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkO3NlUyPDl4OEG=
UW228-3 NUjNO25xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PLZVAvODFvM{CwJO69VQ>? MUe0PEBp MmrjSG1UVw>? NIfwUpZKSzVyPUCuPVnDqM7:TR?= NXj2fIxCOjVzMUmxPFU>
NSCs MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CxXlAvODFvM{CwJO69VQ>? MkDwOFghcA>? NWqySmZbTE2VTx?= M4X2S2lEPTB;MD6zMVPDqM7:TR?= MoLxNlUyOTlzOEW=
MKL-1  MVrGeY5kfGmxbjDBd5NigQ>? MXSxNE0yODByIH7N Mof6OEBl MmHtbY5lfWOnczD0bIUhcW6mdXP0bY9vKG:oIF3IR{1KKGW6cILld5Nqd25? NVPQUXpIOjVzMU[3OVQ>
MCF7 EV NH3mZ3lHfW6ldHnvckBCe3OjeR?= NXT1T3pDOTBvMUCwJO69VQ>? MWGy5qCKcA>? NED4eYhqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? MVmyOVA5QDJyMx?=
MCF 7BMI1 Mo\rSpVv[3Srb36gRZN{[Xl? M1PqOFExNTFyMDFOwG0> NHLzXVcz6oDLaB?= NIDwUZdqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? M{fWWlI2ODh6MkCz
MCF7 EV NW\vfpBmTnWwY4Tpc44hSXO|YYm= M3zwTVExNTFyMDFOwG0> MYOy5qCKcA>? NWOzfnJXTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NUD6c3ZmOjVyOEiyNFM>
MCF7 BMI1 M1jaUmZ2dmO2aX;uJGF{e2G7 M{\tNVExNTFyMDFOwG0> MmTzNwKBkWh? NVvKd295TVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v MorENlUxQDh{MEO=
HepG2 NFz4bJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq4TmZ3TE2VT9Mg M{\VPWlEPTB;M{CuNVbDqMLzwrCwMlUxyqEQvF2= NIrGZpQzPTB5OEOxNS=>
MOLT-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:zSG1UV8Li MnjMTWM2OD1yLkC1NeKhyrIEoECuNFAzyqEQvF2= MX6yOVA4QDNzMR?=
HT1080 MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjtNU0yODBizszN NHnEeVc1NzJ2L{S4JIg> NYm3[YpvTE2VT9Mg NYXkSHNWcW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u M4\m[lI2ODd6ME[0
HT1080 MnfwSpVv[3Srb36gRZN{[Xl? NF\JU2YxNjByMEGtNVAxKM7:TR?= NUXYbXRPOS1{NDDo NELWSlJFVVORwrC= NIHzcFZqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MmK4NlUxPzhyNkS=
HT1080 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PjWFAvODByMT2xNFAh|ryP NFu3ZpozPCCq MnHYSG1UV8Li MkDRZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= M4rMV|I2ODd6ME[0
HD-MY-Z MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OzSFI1NzR6L{eyJIg> MXTJR|Ux97zgMUCwJO69VQ>? NHrubmYzPTB2OEKzOi=>
DOHH-2 NVLoVWllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nOc|I1KGh? MmqwTWM2OO,:nkGwNEDPxE1? NWTzflQ3OjVyNEiyN|Y>
DOHH-2 NFywbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\qOFghcA>? NIfa[3RKSzVyPUG5MlnDqM7:TR?= MYmyOVA1QDJ|Nh?=
DOHH-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXuO|IhcA>? MV3JR|UxRTYEoN88US=> MW[yOVA1QDJ|Nh?=
REH M3\VW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[yOEBp MX7JR|UxRTBwMEK3xsDPxE1? MmSwNlUxPDh{M{[=
REH NVHhSFFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHLOG01QCCq MmTaTWM2OD1yLkCxOOKh|ryP MYeyOVA1QDJ|Nh?=
REH NF;PfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXVS3NQPzJiaB?= NYLwfmxLUUN3ME2wMlAyPcLizszN M2D5eVI2ODR6MkO2
HH NUDkWHp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfRPYMzPCCq MlTBTWM2OD1zMESuO:Kh|ryP NXTFSHFuOjVyNEiyN|Y>
HH MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPFWXVGPDhiaB?= NYnPOlhmUUN3ME20PE43yqEQvF2= Ml;GNlUxPDh{M{[=
HH MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;XW|czKGh? NYDKWGF4UUN3ME2xOE44yqEQvF2= MnTYNlUxPDh{M{[=
HuT-78 NIPPOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvVe|czPCCq MojHTWM2OD17LkRCpO69VQ>? MVmyOVA1QDJ|Nh?=
HuT-78 NFzMNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TaS|Q5KGh? M3GwW2lEPTB;ND6zxsDPxE1? NHzCSmMzPTB2OEKzOi=>
HuT-78 NVfMTlEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV63NkBp MUjJR|UxRTRwMtMg{txO NFfMZ|EzPTB2OEKzOi=>
OPM-2 M2fufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYeyOEBp MlH6TWM2OD1{ND6xxsDPxE1? NFfzfIozPTB2OEKzOi=>
OPM-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz6OFghcA>? M2LnR2lEPTB;NNMg{txO M2PpWlI2ODR6MkO2
OPM-2 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe3NkBp NETpXZRKSzVyPUGuN:Kh|ryP NHTNU2QzPTB2OEKzOi=>
RPMI-8226 NUi3[GhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XyW|I1KGh? MXLJR|UxRTFyNj62xsDPxE1? MX6yOVA1QDJ|Nh?=
RPMI-8226 MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Xqc|Q5KGh? Mk[3TWM2OD17MT6xxsDPxE1? M1K4fFI2ODR6MkO2
RPMI-8226 NGDsUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzuO|IhcA>? M4G4O2lEPTB;MUSuPeKh|ryP MlLFNlUxPDh{M{[=
U-266 M4P3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jkRlI1KGh? Ml7zTWM2OD16Nj6yxsDPxE1? NWLEU25uOjVyNEiyN|Y>
U-266 NEPJVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe0PEBp NGrYSIVKSzVyPU[4MlTDqM7:TR?= MU[yOVA1QDJ|Nh?=
U-266 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG3NkBp NVL3ZZQ2UUN3ME2yO{41yqEQvF2= NV3TWmZjOjVyNEiyN|Y>
Kelly NUC1SFZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXUbJhUOC1zMDFOwG0> NYLCcYdpPzMEoHi= NWfMfHdRUUN3ME2xMlUyQMLizszN NYDXNIFUOjVyMEi5NFA>
SH-SY5Y  M4\xdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHF[W0xNTFyIN88US=> NX3SZWZwPzMEoHi= MUfJR|UxRTBwN{W0xsDPxE4EoB?= M4TZflI2ODB6OUCw
SK-N-AS NVXPb2M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nGR|AuOTBizszN NX;EV5h{PzMEoHi= NIXPSmNKSzVyPUGuO|EzyqEQvF5CpC=> MXuyOVAxQDlyMB?=
SK-N-DZ NHTIfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH62[moxNTFyIN88US=> NV;rRVdGPzMEoHi= MYLJR|UxRTVwNEi1xsDPxE1? M{\3VlI2ODB6OUCw
HepG2 NEHKToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTJSmE1QMLiaB?= NGXRTZpFVVORwrC= M13MOWlEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= NFHBOXgzPDl7NkGzOi=>
A549 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq0POKhcA>? M3ewcWROW00EoB?= M4C3d2lEPTB;MkSxMlnDqMLzwrCzNU4zO8LizszN MVOyOFk6PjF|Nh?=
MCF7 M3fLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfVOpE1QMLiaB?= M3fBWGROW00EoB?= NFvKR3VKSzVyPUixMlA6yqEEsdMgNVQvOjIEoN88US=> M4r6[|I1QTl4MUO2
HL-60  MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPzO|LDqGh? MXLJR|UxRTBwMUNihKXPxE1? MkLwNlQ6QTNyMUS=
HL-60[R] MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPPTHl3PzMEoHi= NEfsdYZKSzVyPUOuNVLjiIYQvF2= NVHxUlZROjR7OUOwNVQ>
MIAPACA NUXHVYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne1S2k2OD1zLkOgxtEhOC5yMzFOwG0> Mn\CNlQ6PTN6MkG=
MCF-7 NHHhSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrjOGVIUTVyPUCuNlUhyrFiMD6xJO69VQ>? Mor6NlQ6PTN6MkG=
HeLa M4\Uc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXryW2V6T0l3ME2wMlY1KMLzIECuOEDPxE1? NX;oUlFyOjR7NUO4NlE>
MO59K  M1LoUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrkZYc4KGR? NG\xOZRKSzVyPUCuNVfjiIYQvF2= M2SzV|I1QTV|NU[x
MO59J NGPq[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULZTJBiPyCm MXHJR|UxRTBwMfMAie69VQ>? M2LyT|I1QTV|NU[x
ME 180 M3T1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX60POKhcMLi MU\JR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? NEW1fo8zPDl3M{CyOy=>
MCF-7 M{\OWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fuflQ5yqCqwrC= M3nOXWlEPTB;MkOuPUDDuSByLkRihKXPxE1? MV6yOFk2OzB{Nx?=
HeLa NXHtSVdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfOZok3PDkEoHlCpC=> MWTJR|UxRTRwN{GgxtEhOS524pEF{txO M1;jb|I1QTV|MEK3
MDA-MB-453 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\lSlQ5yqCqwrC= M{jLcWlEPTB;MUKuOUDDuSByLki15qCG|ryP NIjlT24zPDl3M{CyOy=>
MDA-MB-231 M37zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzDOFjDqGkEoB?= NGO2N3ZKSzVyPUK0MlIzKMLzIEKuPVTjiIYQvF2= NXLwTFNCOjR7NUOwNlc>
PC-3 NYPSWII4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG0POKhcMLi NF;QXXhKSzVyPUG0MlQhyrFiMz6yN-KBjc7:TR?= M3jSOlI1QTV|MEK3
HT-29 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjKOlUxPDkEoHlCpC=> MoDWTWM2OD1{MT60OUDDuSB|Lki35qCG|ryP NHvvc|MzPDl3M{CyOy=>
BGC-823 NXfCd3JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XBW|Q5yqCqwrC= M1\tUGlEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= NGLhUo0zPDd7M{i3Oy=>
HeLa NUexTXJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm0POKhcMLi NXvBeZFKUUN3ME2yNFkvQTBiwsGgNVMvPDJi4pEF{txO MVSyOFc6Ozh5Nx?=
A549 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe0RZI1QMLiaNMg NVi0ZXZvUUN3ME2xN|kvPTRiwsGgO{4xPeLChd88US=> NY\ibHl6OjR5OUO4O|c>
HK-2 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXCUXVrPDkEoHlCpC=> M3LaRmlEPTB;OT6xO{DDuSBzLkW45qCG|ryP NV20NHVXOjR5OUO4O|c>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
体内研究 Etoposide 作用于Lewis 肺癌,诱导肿瘤免疫。Etoposide按50 mg/kg剂量单独腹腔注射给药注射了Lewis肺癌细胞 (3LL)的C57B1/6小鼠,诱导60%存活。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[5]
- 合并

Topoisomerase II 活性测定:

制备核提取物,进行核分离。在Topoisomerase II去连环过程中获得去连环百分数而计算Topoisomerase II的活性。氚标记的kinoplast DNA (KDNA 0.22 μg)作为底物。Etoposide 与 Topoisomerase II在37°C 下温育30分钟,然后加入1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止。通过Etoposide获得去连环百分数和 Topoisomerase II 抑制情况。
细胞实验:[5]
- 合并
  • Cell lines: 人类胶质瘤细胞系CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 小时
  • Method: Etoposide处理后,使用含有0.03%胰蛋白酶和0.27 mM乙二胺四乙酸(EDTA)的磷酸盐缓冲液(PBS)将细胞从培养皿中移去,然后在培养皿中稀释到适当数目,获得20到200个菌落。12天后,使用甲醇-乙酸固定培养基,使用结晶紫进行染色,并计数超过50个细胞的菌落。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 携带血管肉瘤移植瘤ISOS-1 的小鼠
  • Dosages: 10 mg/kg
  • Administration: 从实验第7天开始,每天腹腔注射,持续5天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 588.56
化学式

C29H32O13

CAS号 33419-42-0
储存条件 粉状
溶于溶剂
别名 VP-16, VP-16213

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Tags: 购买Etoposide | Etoposide供应商 | 采购Etoposide | Etoposide价格 | Etoposide生产 | 订购Etoposide | Etoposide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID